CMPI Checkmate Pharmaceuticals, Inc. Stock Quote

CMPI [NASD]

Index	-	P/E	-	EPS (ttm)	-2.92	Insider Own	20.20%	Shs Outstand	21.63M	Perf Week	0.38%
Market Cap	231.63M	Forward P/E	-	EPS next Y	-2.28	Insider Trans	-25.50%	Shs Float	19.66M	Perf Month	1.06%
Income	-63.10M	PEG	-	EPS next Q	-0.75	Inst Own	77.90%	Short Float	0.40%	Perf Quarter	255.94%
Sales	-	P/S	-	EPS this Y	-42.80%	Inst Trans	6.45%	Short Ratio	0.37	Perf Half Y	193.30%
Book/sh	2.54	P/B	4.13	EPS next Y	24.50%	ROA	-75.00%	Target Price	12.50	Perf Year	55.33%
Cash/sh	2.72	P/C	3.85	EPS next 5Y	45.10%	ROE	-83.90%	52W Range	2.00 - 10.50	Perf YTD	265.85%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	0.00%	Beta	-
Dividend %	-	Quick Ratio	5.20	Sales past 5Y	-	Gross Margin	-	52W Low	425.00%	ATR	0.04
Employees	30	Current Ratio	5.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	88.82	Volatility	0.23% 0.37%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-12.10%	Profit Margin	-	Rel Volume	0.28	Prev Close	10.48
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 29 AMC	Payout	-	Avg Volume	216.04K	Price	10.50
Recom	1.70	SMA20	0.70%	SMA50	46.89%	SMA200	129.59%	Volume	59,987	Change	0.19%

May-26-22 05:01PM	University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-12-22 04:30PM	Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update GlobeNewswire
Apr-20-22 11:16AM	Regeneron (REGN) to Buy Checkmate Pharmaceuticals for $250M Zacks
Apr-19-22 02:58PM	Why Checkmate Pharmaceuticals Stock Is Rocketing Higher Today Motley Fool +329.46%
09:00AM	Regeneron to Acquire Checkmate Pharmaceuticals in $250m Deal Investing.com
08:11AM	Midday Stock Movers: Plug Power, WeWork, Checkmate Pharmaceuticals Investing.com
07:00AM	Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types GlobeNewswire
Apr-08-22 01:01PM	Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Mar-29-22 04:30PM	Checkmate Pharmaceuticals Announces Full Year 2021 Financial Results and Provides Business Update GlobeNewswire
Mar-08-22 04:30PM	Checkmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Feb-10-22 06:14AM	The Petri Dish: Syndax, Checkmate get new CEOs; Biogen stays in biosimilars game American City Business Journals +6.19%
Feb-09-22 08:00AM	Checkmate Pharmaceuticals Appoints Alan Bash as President and CEO GlobeNewswire +17.34%
Jan-31-22 04:30PM	Checkmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M.D. to its Board of Directors GlobeNewswire +11.42%
Jan-11-22 05:36AM	One Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) insider upped their stake by 2.5% in the previous year Simply Wall St.
Jan-03-22 04:30PM	Checkmate Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference GlobeNewswire
Dec-20-21 07:00AM	Checkmate Pharmaceuticals Strengthens Board of Directors with Appointment of Joy Yan, M.D., Ph.D. GlobeNewswire +10.53%
07:00AM	Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Multi-Indication Trial Using Vidutolimod GlobeNewswire
Nov-15-21 04:30PM	Checkmate Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference GlobeNewswire -5.18%
Nov-12-21 07:05AM	Checkmate Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update GlobeNewswire
07:01AM	Checkmate Pharmaceuticals Presents Final Clinical Data for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting GlobeNewswire
Nov-11-21 04:30PM	Checkmate Pharmaceuticals to Present at the Jefferies London Healthcare Conference GlobeNewswire
Nov-01-21 08:01AM	Checkmate Pharmaceuticals Announces Final Data Presentation for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting GlobeNewswire +8.49%
Oct-27-21 04:30PM	Checkmate Pharmaceuticals Announces CEO Transition GlobeNewswire
Oct-20-21 04:30PM	Checkmate Pharmaceuticals Announces Webcast on Innate Immune Modulators and Vidutolimod (CMP-001) GlobeNewswire
Oct-13-21 07:55AM	We're Keeping An Eye On Checkmate Pharmaceuticals' (NASDAQ:CMPI) Cash Burn Rate Simply Wall St.
Sep-14-21 04:30PM	Checkmate Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference GlobeNewswire
Sep-07-21 07:00AM	Checkmate Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
Aug-12-21 04:30PM	Checkmate Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update GlobeNewswire
Aug-02-21 04:15PM	Checkmate Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference Business Wire +5.18%
Jul-15-21 02:34AM	Have Insiders Been Buying Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Shares? Simply Wall St.
May-20-21 04:30PM	Checkmate Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference GlobeNewswire
May-13-21 04:10PM	Checkmate Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Update on Recent Progress GlobeNewswire
May-10-21 06:00AM	Checkmate Pharmaceuticals Announces Clinical Supply Agreement with Regeneron to Evaluate Vidutolimod (CMP-001) in Combination with Libtayo® (cemiplimab) GlobeNewswire -8.60%
May-04-21 07:00AM	Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Potential Registration Trial of Vidutolimod (CMP-001) in Patients with Anti-PD-1 Refractory Advanced Melanoma GlobeNewswire
Apr-28-21 04:30PM	Checkmate Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference GlobeNewswire
Apr-19-21 06:00AM	Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Head and Neck Cancer Trial GlobeNewswire -6.75%
Apr-16-21 04:27AM	Here's Why We're Watching Checkmate Pharmaceuticals' (NASDAQ:CMPI) Cash Burn Situation Simply Wall St. -5.52%
Apr-12-21 08:36AM	Checkmate Pharmaceuticals Releases Clinical Data For Vidutolimod And Pembrolizumab Combo SmarterAnalyst -21.48%
Apr-11-21 04:01PM	Checkmate Pharmaceuticals Presents New Clinical Trial Translational Data with Vidutolimod at the 2021 American Association for Cancer (AACR) Annual Meeting GlobeNewswire
Apr-09-21 02:16PM	7 Beaten Down Stocks with Significant Insider Buying InvestorPlace
Mar-29-21 04:30PM	Checkmate Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Update on Recent Progress GlobeNewswire -11.92%
Mar-10-21 04:30PM	Checkmate Pharmaceuticals to Present Data at the 2021 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Jan-04-21 04:30PM	Checkmate Pharmaceuticals Announces Key Additions to Executive Management Team GlobeNewswire
Dec-20-20 02:14AM	Insider Buying: The Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Founder Just Bought US$71k Worth Of Shares Simply Wall St.
Dec-08-20 07:00AM	Checkmate Pharmaceuticals Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate CMP-001 in Combination with Nivolumab GlobeNewswire +13.09%
Dec-01-20 06:30PM	Is Checkmate Pharmaceuticals (CMPI) A Good Stock To Buy Now? Insider Monkey
Nov-13-20 07:00AM	Checkmate Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides an Update on Recent Progress GlobeNewswire
Nov-09-20 09:00AM	Checkmate Pharmaceuticals Presents Updated Clinical Data with CMP-001 at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting GlobeNewswire +16.31%
Nov-07-20 08:58AM	We Think Checkmate Pharmaceuticals (NASDAQ:CMPI) Can Afford To Drive Business Growth Simply Wall St.
Nov-03-20 07:00AM	Checkmate Pharmaceuticals to Present at the Upcoming Jefferies Virtual London Healthcare Conference GlobeNewswire +6.17%
Oct-15-20 09:20AM	Checkmate Pharmaceuticals Announces Data Presentations for CMP-001 at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting GlobeNewswire
Sep-23-20 07:00AM	Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies GlobeNewswire
Sep-18-20 07:00AM	Checkmate Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides an Update on Recent Progress GlobeNewswire -6.81%
Sep-09-20 01:00AM	Kuros Biosciencess licensee Checkmate Pharmaceuticals completes its IPO on NASDAQ GlobeNewswire +7.47%
Aug-06-20 09:17PM	Checkmate Pharmaceuticals Announces Pricing of Initial Public Offering GlobeNewswire

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naive neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
venBio Global Strategic Fund I	10% Owner	May 16	Sale	10.45	95,800	1,001,100	2,155,930	May 17 05:12 PM
venBio Global Strategic Fund I	10% Owner	May 13	Sale	10.45	35,850	374,464	2,251,730	May 17 05:12 PM
venBio Global Strategic Fund I	10% Owner	May 12	Sale	10.39	124,525	1,294,313	2,287,580	May 12 08:47 PM
venBio Global Strategic Fund I	10% Owner	May 11	Sale	10.38	17,700	183,641	2,412,105	May 12 08:47 PM
venBio Global Strategic Fund I	10% Owner	May 10	Sale	10.38	18,676	193,870	2,429,805	May 12 08:47 PM
venBio Global Strategic Fund I	10% Owner	May 09	Sale	10.37	17,600	182,582	2,448,481	May 09 06:58 PM
venBio Global Strategic Fund I	10% Owner	May 06	Sale	10.37	48,334	501,233	2,466,081	May 09 06:58 PM
venBio Global Strategic Fund I	10% Owner	May 05	Sale	10.37	20,743	215,105	2,514,415	May 09 06:58 PM
venBio Global Strategic Fund I	10% Owner	May 04	Sale	10.37	37,500	388,924	2,535,158	May 04 07:30 PM
venBio Global Strategic Fund I	10% Owner	May 03	Sale	10.37	79,475	824,434	2,572,658	May 04 07:30 PM
venBio Global Strategic Fund I	10% Owner	May 02	Sale	10.38	153,700	1,595,975	2,652,133	May 04 07:30 PM
venBio Global Strategic Fund I	10% Owner	Apr 29	Sale	10.38	69,230	718,663	2,805,833	Apr 29 05:50 PM
venBio Global Strategic Fund I	10% Owner	Apr 28	Sale	10.38	73,400	761,936	2,875,063	Apr 29 05:50 PM
venBio Global Strategic Fund I	10% Owner	Apr 27	Sale	10.38	47,396	491,980	2,948,463	Apr 29 05:50 PM
venBio Global Strategic Fund I	10% Owner	Apr 26	Sale	10.38	64,683	671,558	2,995,859	Apr 26 06:40 PM
venBio Global Strategic Fund I	10% Owner	Apr 25	Sale	10.39	27,668	287,404	3,060,542	Apr 26 06:40 PM
venBio Global Strategic Fund I	10% Owner	Apr 22	Sale	10.39	37,430	388,834	3,088,210	Apr 26 06:40 PM
venBio Global Strategic Fund I	10% Owner	Apr 21	Sale	10.38	62,200	645,866	3,125,640	Apr 21 08:54 PM
venBio Global Strategic Fund I	10% Owner	Apr 20	Sale	10.39	85,611	889,387	3,187,840	Apr 21 08:54 PM
venBio Global Strategic Fund I	10% Owner	Apr 19	Sale	10.42	399,923	4,165,238	3,273,451	Apr 21 08:54 PM
Novo Holdings A/S	10% Owner	Feb 25	Sale	2.70	300	811	2,161,990	Feb 25 06:21 PM
Novo Holdings A/S	10% Owner	Feb 24	Sale	2.83	5,990	16,979	2,162,290	Feb 25 06:21 PM
Novo Holdings A/S	10% Owner	Feb 23	Sale	2.90	1,820	5,277	2,168,280	Feb 25 06:21 PM
Krieg Arthur M	Chief Scientific Officer	Jun 18	Buy	6.04	7,224	43,633	815,734	Jun 21 04:26 PM
Krieg Arthur M	Chief Scientific Officer	Jun 16	Buy	6.18	3,578	22,112	808,510	Jun 17 04:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience